☆ 4.6 Letter

Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Get Full Text
Add to Collection

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 184, Issue 3, Pages 462-465

Publisher

WILEY
DOI: 10.1111/bjh.15110

Keywords

lymphoma; rituximab; ofatumumab; monoclonal antibody; infusion-related reaction

Categories

Hematology

Funding

  1. UCL/UCLH Biomedical Research Centre

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.